2-(1-Hydroxyethyl)-3-hydroxy-pyran-4(1H)-one | 4940-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 2-(1-Hydroxyethyl)-3-hydroxy-pyran-4(1H)-one
• 英文别名: 2-(1'-hydroxyethyl)-3-hydroxypyran-4(1H)-one；3-hydroxy-2-(1-hydroxyethyl)pyran-4-one
• CAS: 4940-10-7
• 化学式: C₇H₈O₄
• 分子量: 156.138
• InChiKey: OYQBJBXMWZKGPM-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132 °C
• 沸点：
  379.6±42.0 °C(Predicted)
• 密度：
  1.463±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(1-Hydroxyethyl)-3-hydroxy-pyran-4(1H)-one 生成 1-Ethyl-2-(1-methoxyethyl)-3-benzyloxy-pyridin-4(1H)-one
  参考文献：
  名称：

  Orally active iron (III) chelators

  摘要：

  提供一种化合物，其为一种新颖的3-羟基吡啶-4-酮化合物，其化学式为I，其中R为氢或在体内代谢中被去除以提供游离羟基化合物的基团，R1为脂肪烃基团或被羟基或羧酸酯、磺酸酯或其C1-6烷氧基、C6芳基氧基或C7-10芳基烷氧基所取代的脂肪烃基团，R3从氢和C1-6烷基中选择；R4从氢、C1-6烷基和如R2所述的基团中选择；其中R2从以下基团中选择：—CONH—R5 (i)—CH2NHCO—R5 (ii)—SO2NH—R5 (iii)—CH2NHSO2—R5 (iv)—CR6R6OR7 (v)—CONHCOR5 (viii) 其中R5从氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-13烷基、芳基和C7-13芳基烷基中选择，R6独立选择自氢、C1-13烷基、芳基和C7-13芳基烷基，R7从氢、C1-13烷基、芳基和C7-13芳基烷基中选择，或任何这种化合物的药用盐；但是当R7为氢时，R6不选择自芳基，并且化合物不是1-乙基-2-(1'-羟乙基)-3-羟基吡啶-4-酮。

  公开号：

  US06335353B1
• 作为产物：
  描述：

  2,5-二氢-2,5-二甲氧基糠基醇 在 sodium hydroxide 、 甲酸 、 溴 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-(1-Hydroxyethyl)-3-hydroxy-pyran-4(1H)-one
  参考文献：
  名称：

  Synthesis, Physicochemical Characterization, and Biological Evaluation of 2-(1‘-Hydroxyalkyl)-3-hydroxypyridin-4-ones:  Novel Iron Chelators with Enhanced pFe³⁺ Values

  摘要：

  The synthesis of a range of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones as bidentate iron(III) chelators with potential for oral administration is described. The pK(a) values of the ligands and the stability constants of their iron(III) complexes have been determined. Results indicate that the introduction of a 1'-hydroxyalkyl group at the 2-position leads to a significant improvement in the pFe(3+) values. Such an effect was found to be greater with the hydroxyethyl substituent than with the hydroxymethyl substituent, particularly in the cases of 1-ethyl-2-(1'-hydroxyethyl)-3-hydroxypyridin-4-one (pFe(3+) = 21.4) and 1,6-dimethyl-2-(1'-hydroxyethyl)-3-hydroxypyridin-4-one (pFe(3+) = 21.5) where an enhancement on pFe(3+) values in the region of two orders of magnitude is observed, Bs compared with Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (pFe(3+) = 19.4). The ability of these novel 3-hydroxypyridin-4-ones to facilitate the iron excretion in bile was investigated using a [Fe-59]ferritin-loaded rat model. Chelators and prodrug chelators possessing high pFe(3+) values show great promise in their ability to remove iron under in vivo conditions.

  DOI：

  10.1021/jm991080o

文献信息

• 3-hydroxypyridin-4-one derivatives as pharmaceutical compositions
  申请人：BRITISH TECHNOLOGY GROUP LTD

  公开号：EP0494754A1

  公开（公告）日：1992-07-15

  3-Hydroxypyridin-4-ones of formula (I) in which R₁ is selected from hydrogen, C₁₋₃ aliphatic hydrocarbon groups, 2-hydroxyethyl, C₁₋₄ aliphatic hydrocarbon groups substituted by a single carboxy, sulpho, sulphamoyl or N-methyl or N-ethyl sulphamoyl group, and an ethyl group substituted at the 1-or 2-position by a carboxy, sulpho, sulphamoyl or N-methyl or N-ethyl sulphamoyl group and at the 2-position by a hydroxy group, and R₂, R₃ and R₄ are each separately selected from hydrogen, C₁₋₃ aliphatic hydrocarbon groups, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-methoxymethyl, C₁₋₄ aliphatic hydrocarbon groups substituted by a single carboxy, sulpho, sulphamoyl or N-methyl or N-ethyl sulphamoyl group, and an ethyl group substituted at the 1-or 2-position by a carboxy, sulpho, sulphamoyl or N-methyl or N-ethyl sulphamoyl group and at the 2-position by a hydroxy group, but with the provisos firstly that one of R₁ to R₄ is a C₁₋₄ aliphatic hydrocarbon group substituted by a single carboxy, sulpho, sulphamoyl or N-methyl or N-ethyl sulphamoyl group, or an ethyl group substituted at the 1- or 2-position by a carboxy, sulpho, sulphamoyl or N-methyl or N-ethyl sulphamoyl group and at the 2-position by a hydroxy group, secondly that either R₂ or R₃ is a group other than hydrogen and thirdly that the total number of atoms other than hydrogen present in R₁ to R₄ is no more than eight, the compound optionally being in the form of a physiologically acceptable salt and/or pro-drug thereof, are of value for the treatment of conditions caused by iron dependent parasites, particularly malaria.

  式(I)中，3-羟基吡啶-4-酮，其中R₁选自氢，C₁₋₃脂肪烃基，2-羟乙基，C₁₋₄脂肪烃基，被单个羧基，磺酰基，磺酰胺基或N-甲基或N-乙基磺酰胺基取代，以及在1-或2-位置被羧基，磺酰基，磺酰胺基或N-甲基或N-乙基磺酰胺基取代的乙基基团，在2-位置被羟基取代；R₂，R₃和R₄各自单独选自氢，C₁₋₃脂肪烃基，羟甲基，1-羟基乙基，2-羟基乙基，2-甲氧基甲基，C₁₋₄脂肪烃基，被单个羧基，磺酰基，磺酰胺基或N-甲基或N-乙基磺酰胺基取代，以及在1-或2-位置被羧基，磺酰基，磺酰胺基或N-甲基或N-乙基磺酰胺基取代的乙基基团，在2-位置被羟基取代，但前提是首先R₁至R₄中有一个是被单个羧基，磺酰基，磺酰胺基或N-甲基或N-乙基磺酰胺基取代的C₁₋₄脂肪烃基，或在1-或2-位置被羧基，磺酰基，磺酰胺基或N-甲基或N-乙基磺酰胺基取代的乙基基团，在2-位置被羟基取代；其次，R₂或R₃为除氢之外的基团；第三，除氢之外的原子总数不超过8个。该化合物可选为生理上可接受的盐和/或前药形式，对于治疗由铁依赖性寄生虫引起的疾病特别是疟疾具有价值。
• [EN] NOVEL ORALLY ACTIVE IRON (III) CHELATORS<br/>[FR] NOUVEAUX CHELATEURS DU FER (III) AGISSANT PAR LA VOIE ORALE
  申请人：BTG INTERNATIONAL LIMITED

  公开号：WO1998054138A1

  公开（公告）日：1998-12-03

  (EN) A novel 3-hydroxypyridin-4-one compound of formula (I) is provided, wherein R is hydrogen or a group that is removed by metabolism $i(in vivo) to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6alkyl; and R4 is selected from hydrogen and C1-6alkyl, C1-6alkyl and a group as described for R2; characterised in that R2 is selected from groups (i) -CONH-R5, (ii) -CH2NHCO-R5, (iii) -SO2NH-R5, (iv) -CH2NHSO2-R5, (v) -CR6R6OR7, (viii) -CONHCOR5, wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-13alkyl, aryl and C7-13aralkyl, R6 is independently selected from hydrogen, C1-13alkyl, aryl and C7-13aralkyl, and R7 is selected from hydrogen, C1-13alkyl, aryl and C7-13aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R7 is hydrogen, R6 is not selected from aryl and with the proviso that the compound is not 1-ethyl-2-(1'-hydroxyethyl)-3-hydroxypyridin-4-one.(FR) Nouveau composé 3-hydroxypyridin-4-one de la formule (I) dans laquelle R représente un hydrogène ou un groupe extrait par métabolisme $i(in vivo) dans le but de fournir composé hydroxy libre; R1 représente un groupe hydrocarbure aliphatique ou un groupe hydrocarbure aliphatique substitué par un groupe hydroxy ou un ester d'acide carboxylique, un ester de sulphoacide, un éther C1-6alcoxy, ou C7-10aryloxy ou aralkyloxy de ce groupe hydrocarbure; R3 est sélectionné parmi l'hydrogène et un C1-6alkyle; et R4 est sélectionné parmi l'hydrogène, un C1-6alkyle et un groupe tel que décrit pour R2. Ce composé est caractérisé en ce que R2 est sélectionné parmi des groupes (i) -CONH-R5; (ii) -CH2NHCO-R5; (iii) -SO2NH-R5; (iv) -CH2NHSO2-R5; (v) -CR6R6OR7; (viii) -CONHCOR5 dans lesquels R5 est sélectionné parmi l'hydrogène et un C1-13alkyle, aryle et C7-13aralkyle éventuellement substitués par un hydroxy, alcoxy ou aralcoxy; R6 est indépendamment sélectionné parmi l'hydrogène, un C1-13alkyle, aryle et C7-13aralkyle; et R7 est sélectionné parmi l'hydrogène, un C1-13alkyle, aryle et C7-13aralkyle. L'invention concerne en outre un sel pharmaceutiquement acceptable de n'importe lequel des composés de ce type et ce, à condition que lorsque R7 représente de l'hydrogène, R6 ne soit pas sélectionné parmi les aryles et à condition que le composé ne soit pas une 1-éthyl-2-(1'hydroxyéthyl)-3-hydroxypyridin-4-one.

  提供一种新型的3-羟基吡啶-4-酮化合物，其化学式为(I)，其中R为氢或一种在代谢中被去除以提供自由羟基化合物的基团，R1为脂肪烃基或被羟基或羧酸酯、磺酸酯或其C1-6烷氧基、C6-芳氧基或C7-10芳基烷氧基取代的脂肪烃基，R3选自氢和C1-6烷基；R4选自氢和C1-6烷基、C1-6烷基和R2所述的基团；其特征在于R2选自(i) -CONH-R5、(ii) -CH2NHCO-R5、(iii) -SO2NH-R5、(iv) -CH2NHSO2-R5、(v) -CR6R6OR7、(viii) -CONHCOR5，其中R5选自氢和可选地被羟基、烷氧基或芳基烷氧基取代的C1-13烷基、芳基和C7-13芳基烷基，R6独立选自氢、C1-13烷基、芳基和C7-13芳基烷基，R7选自氢、C1-13烷基、芳基和C7-13芳基烷基，或其药学上可接受的盐，但当R7为氢时，R6不得选自芳基，并且该化合物不得为1-乙基-2-(1'-羟基乙基)-3-羟基吡啶-4-酮。
• Novel orally active iron (III) chelators
  申请人：BTG International Limited.

  公开号：US20020068758A1

  公开（公告）日：2002-06-06

  A novel 3-hydroxypyridinone compound of formula I is provided 1 wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R 1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C 1-6 alkoxy, C 6 -aryloxy or C 7-10 aralkoxy ether thereof, R 3 is selected from hydrogen and C 1-6 alkyl; and R 4 is selected from hydrogen, C 1-6 alkyl and a group as described for R 2 ; characterized in that R 2 is selected from groups (i) —CONH—R 5 (ii) —CH 2 NHCO—R 5 (iii) —SO 2 NH—R 5 (iv) —CH 2 NHSO 2 —R 5 (v) —CR 6 R 6 OR 7 (viii) —CONHCOR 5 wherein R 5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C 1-13 alkyl, aryl and C 7-13 aralkyl, R 6 is independently selected from hydrogen, C 1-13 alkyl, aryl and C 7-13 aralkyl, and R 7 is selected from hydrogen, C 1-13 alkyl, aryl and C 7-13 aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R 7 is hydrogen, R 6 is not selected from aryl and with the proviso that the compound is not 1-ethyl-2-(1′-hydroxyethyl)-3-hydroxypyridin-4-one.

  提供了一种新的3-羟基吡啶酮化合物，其化学式为I，其中R为氢或代谢在体内提供自由羟基化合物的基团，R1为脂肪族烃基或被羟基基团或羧酸酯、磺酸酯或其C1-6烷氧基、C6-芳氧基或C7-10芳基烷氧基所取代的脂肪族烃基，R3选自氢和C1-6烷基；R4选自氢、C1-6烷基和如R2所述的基团，其中R2选自以下基团：(i) —CONH—R5(ii) —CH2NHCO—R5(iii) —SO2NH—R5(iv) —CH2NHSO2—R5(v) —CR6R6OR7(viii) —CONHCOR5，其中R5选自氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-13烷基、芳基和C7-13芳基烷基，R6独立选自氢、C1-13烷基、芳基和C7-13芳基烷基，R7选自氢、C1-13烷基、芳基和C7-13芳基烷基，或任何这种化合物的药学上可接受的盐，但是当R7为氢时，R6不选自芳基，并且该化合物不是1-乙基-2-(1'-羟乙基)-3-羟基吡啶-4-酮。
• Pyrano &lsqb;3,2-d&rsqb;-1,3-dioxin-8 ones
  申请人：BTG International Limited

  公开号：US06506911B2

  公开（公告）日：2003-01-14

  A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6 alkyl; and R4 is selected from hydrogen, C1-6 alkyl and a group as described for R2; characterised in that R2 is selected from groups (i) —CONH—R5 (ii) —CH2NHCO—R5 (iii) —SO2NH—R5 (iv) —CH2NHSO2—R5 (v) —CR6R6OR7 (viii) —CONHCOR5  wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-3 alkyl, aryl and C7-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl, and R7 is selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R7 is hydrogen, R6 is not selected from aryl and with the proviso that the compound is not l-ethyl-2-(1′hydroxyethyl)-3-hydroxypyridin-4-one.

  提供了一种新型的3-羟基吡啶-4-酮化合物，其化学式为I，其中R是氢或代谢体内去除以提供自由羟基化合物的基团，R1是脂肪烃基或被羟基或羧酸酯、磺酸酯或其C1-6烷氧基、C6-芳氧基或C7-10芳基烷氧基取代的脂肪烃基，R3选自氢和C1-6烷基；R4选自氢、C1-6烷基和R2所述的基团；其特征在于R2选自以下基团(i) —CONH—R5 (ii) —CH2NHCO—R5 (iii) —SO2NH—R5 (iv) —CH2NHSO2—R5 (v) —CR6R6OR7 (viii) —CONHCOR5，其中R5选自氢和可选的羟基、烷氧基或芳基烷氧基取代的C1-3烷基、芳基和C7-13芳基烷基，R6独立选自氢、C1-13烷基、芳基和C7-13芳基烷基，R7选自氢、C1-13烷基、芳基和C7-13芳基烷基，或任何这样化合物的药物可接受的盐；但是当R7为氢时，R6不能选自芳基，并且该化合物不是1-乙基-2-(1'羟乙基)-3-羟基吡啶-4-酮。
• Basic 3-hydroxypyridin-4-ones: Potential antimalarial agents
  作者：Lotfollah S. Dehkordi、Zu D. Liu、Robert C. Hider

  DOI：10.1016/j.ejmech.2007.07.011

  日期：2008.5

  3-Hydroxypyridin-4-ones selectively bind iron under biological conditions and one such compound has found application in the treatment of thalassaemia-linked iron overload. Related molecules have also been demonstrated to possess an antimalarial effect at levels which are non-toxic to mammalian cells. In an attempt to improve the efficiency of such molecules we have investigated the effect of introducing basic nitrogen centres into 3-hydroxypyridin-4-ones in an attempt to achieve targeting to lysosomes and other intracellular acidic vacuoles. Several of the compounds reported in this communication possess enhanced antimalarial activity over that of the simple hydroxypyridinone class. (C) 2007 Elsevier Masson SAS. All rights reserved.